Research article · 17 Jul 2026
Conference abstractPublished 26 Oct 2015
Good Clinical Practice (GCP) and declaration of helsinki
Vydehi Institute of Medical Sciences and Research Centre, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The concept of âÂ?Â?good physicianâÂ?Â? is evident by the Hippocratic Oath (460 BC). In the United States, the first landmark in the regulation of drugs was the Food and Drugs Act of 1906. In 1947, the Nuremberg Code was created as a result of the unethical and horrific experiments carried out during World War II at Nazi war camps by German physicians. However, since 1964, the Declaration of Helsinki has stood as one of the world’s most authoritative statements on ethical standards for human research. The Declaration has undergone six major revisions, most recently in October, 2008. For many years the USFDA has required that foreign clinical studies supporting applications for drug licensure comply with the Declaration. However, on Oct 27, 2008, the FDA formally discontinued its reliance on the Declaration and substituted the International Conference on Harmonization’s Guideline for Good Clinical Practice (GCP). Good Clinical Practice (GCP) is an international ethical and scientific quality standard for the design, conduct, performance, and monitoring, auditing, recording, analyses and reporting of clinical trials. GCP provides assurance that the data and reported results are credible and accurate, and that the rights, integrity and confidentiality of trial subjects are respected and protected. However, several authors have criticized GCP and compared between GCP and the Declaration of Helsinki from time to time. It has been put forward that at a time when the volume of overseas trials is increasing, the FDA’s new policy is troubling. Several requirements in latest revision of Declaration of Helsinki have been highlighted which are absent in GCP.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Developing Drugs.
Commentary · 4 Feb 2026
Vaccine Development and Global Disease Prevention
Commentary · 4 Feb 2026
Transforming Drug Development Through Pharmaceutical Biotechnology
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Developing Drugs
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Pooja Roy”

